Assembly Biosciences, Inc. (ASMB) – What Are Researchers Thinking About This Stock?

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $47.50.

ASMB has been the topic of several research reports. UBS Group assumed coverage on shares of Assembly Biosciences in a research report on Tuesday, September 1st. They set a “buy” rating and a $52.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Mizuho set a $53.00 price target on Assembly Biosciences in a research note on Tuesday, September 1st. Zacks Research upgraded shares of Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a report on Tuesday, August 18th.

Assembly Biosciences Stock Up 3.1%

Shares of Assembly Biosciences stock opened at $23.53 on Friday. The firm has a market capitalization of $479.07 million, a P/E ratio of 23.07 and a beta of 1.15. Assembly Biosciences has a 52 week low of $21.80 and a 52 week high of $39.71. The firm’s 50 day moving average is $28.82 and its two-hundred day moving average is $27.73.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.52. The company had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. As a group, research analysts expect that Assembly Biosciences will post 2.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

A number of institutional investors have recently modified their holdings of ASMB. Seven Fleet Capital Management LP increased its stake in Assembly Biosciences by 671.5% during the second quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock worth $11,903,000 after acquiring an additional 377,000 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Assembly Biosciences during the 2nd quarter worth about $660,000. Stempoint Capital LP increased its position in Assembly Biosciences by 18.3% during the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after purchasing an additional 28,707 shares in the last quarter. Eversept Partners LP acquired a new stake in Assembly Biosciences during the 4th quarter worth approximately $5,431,000. Finally, 683 Capital Management LLC purchased a new position in Assembly Biosciences in the fourth quarter valued at approximately $948,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral diseases. The company’s research programs target viral replication and other essential processes, with an emphasis on treatments that may improve outcomes for patients with limited therapeutic options.

Assembly’s pipeline has included investigational therapies for chronic hepatitis B virus (HBV) infection, including core or capsid assembly modulators designed to interfere with the virus’s life cycle.